Navigation Links
Bionovo Announces Publication of the Paper Detailing the Mechanism of Action of Its Cancer Drug BZL101
Date:4/1/2008

BZL101 selectively kills cancer cells but not normal cells

EMERYVILLE, Calif., April 1 /PRNewswire-FirstCall/ -- Bionovo Inc. (Nasdaq: BNVI) today announced the publication of a peer-reviewed article in the journal Cancer Biology and Therapy that elucidates the molecular mechanisms underlying selective cytotoxic activity of BZL101, the company's drug for advanced breast cancer.

"BZL101 induces cell death in breast cancer cells but not in normal breast cells," said Emma Shtivelman, Ph.D., Director of Cancer Research at Bionovo. "This selective cell killing is based on strong induction by BZL101 of reactive oxygen species (ROS) in tumor cells. The ROS cause extensive DNA damage in tumor cells but not in normal cells, which then leads to the inhibition of glycolysis selectively in tumor cells. This action is most clearly evident from the decrease in the enzymatic activities within the glycolytic pathway and the inhibition of lactate production. The observed inhibition of glycolysis is a key factor in the energetic collapse and death that occurs selectively in breast cancer cells, 'selectively' because tumor cells rely on glycolysis for energy production."

Separately, Isaac Cohen, O.M.D., Bionovo's Chairman and CEO, stated, "The promising selectivity of BZL101 towards cancer cells is based on metabolic differences between highly glycolytic tumor cells and normal cells. Coupled with promising clinical development, BZL101 has the potential to be an important treatment for women with breast cancer, as well as potentially for other cancers. BZL101 could fill an important unmet medical need in cancer treatment."

About BZL101

BZL101 is an oral drug designed for the treatment of advanced breast cancer and panc
'/>"/>

SOURCE Bionovo Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial
2. Kingfisher Announces FDA 510(k) Clearance of Breakthrough KFH Energy for Chronic Pain Sufferers
3. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
4. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
5. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
6. Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF
7. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
8. Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
9. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
10. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
11. IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014  MEDIMETRIKS PHARMACEUTICALS today ... William Resnick have been elected to Medimetriks, ... Mr. Lary, who will serve on Medimetriks, ... investment experience to the Company.  Mr. Lary is ... LLC, a leading institutional investment firm.  Mr. Lary ...
(Date:9/23/2014)... YORK , September 23, 2014 ... pioneer in computer-aided dysmorphology analysis will exhibit at the ... Diego, CA. FDNA will present the latest ... and reference solution, using facial analysis technology. Face2Gene facilitates ... of human malformations from facial photos. The ...
(Date:9/23/2014)... 23, 2014 According to ... Product (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave), Application ... - Global Forecasts to 2019", published by MarketsandMarkets, studies ... period of 2014 to 2019. The market is ... CAGR of 9.6% from 2014 to 2019. ...
Breaking Medicine Technology:Medimetriks Pharmaceuticals, Inc. Welcomes Independent Directors Andrew Lary and William Resnick to its Board of Directors 2FDNA to Exhibit at ASHG2014 Presenting Face2Gene Integrated With London Medical Databases (LMD) Online 2Ablation Technologies Market Worth $3.81 Billion by 2019 2Ablation Technologies Market Worth $3.81 Billion by 2019 3Ablation Technologies Market Worth $3.81 Billion by 2019 4
... Terumo Heart, Inc. today announced that NewYork-Presbyterian Hospital/ ... second U.S. center, and first in the Northeast, ... part of the DuraHeart Bridge-To-Transplant U.S. pivotal trial, ... in up to 40 centers nationwide. The ...
... The American Medical Association (AMA) Foundation announced today the 28 recipients of ... provides $2,500 grants to medical students, physician residents and fellows to conduct ... are conducting research in the following four categories: , , ... , HIV/AIDS , ...
Cached Medicine Technology:Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient 2Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient 3AMA Foundation Announces Seed Grant Research Recipients 2AMA Foundation Announces Seed Grant Research Recipients 3
(Date:9/23/2014)... 23, 2014 Dr. Connie Casad has announced ... to new office space at 12200 Park Central Drive, Suite ... office will be Park Cities Aesthetics, Optimal Health and Wellness, ... announcing her move, Dr. Casad said, “The patients’ comfort and ... select, we want them to always feel like their needs ...
(Date:9/23/2014)... rapidly developing, bringing with its advances promises of ... and treatment interventions. Genetic tests are already ... and hepatitis c virus (HPC), and emerging research ... screen for an individual,s susceptibility to addiction to ... , While there appear to be many benefits ...
(Date:9/23/2014)... -- Few children who take medication for attention-deficit/hyperactivity ... rates vary six-fold across counties in the United ... can manage symptoms for many children with ADHD, ... behavioral therapy (psychotherapy), the Rand Corp. researchers noted. ... 1,500 counties across the United States that included ...
(Date:9/23/2014)... Ill. (September 23, 2014) Both patients and ... screening computed tomography (CT) colonography greatly outweighs the ... tests precipitated by false-positive diagnoses, according to a ... the journal Radiology . , Diagnostic tests ... specific organ. However, when screening for colorectal cancer ...
(Date:9/23/2014)... SOURCE: Solutions from Our Country’s ... made to Rimidi Diabetes and TruClinic ... business solutions to challenges faced by patients and healthcare ... between The Hitachi Foundation, Village Capital, ... with the investment capital, mentoring, and support needed to ...
Breaking Medicine News(10 mins):Health News:Dr. Connie Casad Moving to New Office Location 2Health News:NYU-Mount Sinai Beth Israel study explores drug users' opinions on genetic testing 2Health News:Kids Taking ADHD Drugs Get Little Psychotherapy: Study 2Health News:Patients accept false-positives to achieve diagnostic sensitivity 2Health News:Patients accept false-positives to achieve diagnostic sensitivity 3Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 2Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 3Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 4Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 5
... ... Shows Pointing to Words During Story Time Enhances Children,s Literacy Development , ... Rockville, MD (Vocus) May 4, 2010 -- While ... study suggests that by pointing to the words being read and talking about print, children,s ...
... , ... Show How Women Health Workers Can Save Children,s Lives, Fill Key Health Care Gaps Around the ... Westport, Conn. (Vocus) -- To ... child deaths, countries must invest in women who are front-line health care workers, Save the Children ...
... be an effective preventive measure, researchers say , TUESDAY, May ... be one way to slow the HIV/AIDS epidemic, according to ... greater risk for HIV infection than those not infected with ... 18 to 24, who were uncircumcised, did not have HIV ...
... 4, 2010) Rates of colorectal cancer screening vary ... to data being presented at Digestive Disease Week (DDW) ... as well as utilization rates of virtual and optical ... DDW is the largest international gathering of physicians ...
... ... of the best hospitals and clinics in the world. , ... Monsey, NY (PRWEB) May 4, 2010 -- The new All Time Medical space ... were physically bound by how many people we were able to hire. We literally couldn,t have ...
... The ... provider while more accurately reflecting its strengths and abilities , ... Baltimore, MD (PRWEB) May 4, 2010 -- ... America, is pleased to announce the completion of its rebranding, establishing itself as Tax ...
Cached Medicine News:Health News:New Study Shows Parents How to Increase Their Kid's Success in Reading 2Health News:For a Mother's Day Gift with Lasting Appeal, Invest in Women Health Workers, Says Save the Children 2Health News:For a Mother's Day Gift with Lasting Appeal, Invest in Women Health Workers, Says Save the Children 3Health News:For a Mother's Day Gift with Lasting Appeal, Invest in Women Health Workers, Says Save the Children 4Health News:Men With HPV at Higher Risk for HIV, Study Finds 2Health News:Investigators examine colorectal cancer screening methods among diverse populations 2Health News:Investigators examine colorectal cancer screening methods among diverse populations 3Health News:Investigators examine colorectal cancer screening methods among diverse populations 4Health News:Investigators examine colorectal cancer screening methods among diverse populations 5Health News:Investigators examine colorectal cancer screening methods among diverse populations 6Health News:Investigators examine colorectal cancer screening methods among diverse populations 7Health News:Investigators examine colorectal cancer screening methods among diverse populations 8Health News:Investigators examine colorectal cancer screening methods among diverse populations 9Health News:Investigators examine colorectal cancer screening methods among diverse populations 10Health News:All Time Medical Has Just Moved To Their New, State-Of-The Art Office Situated In The Heart Of The Business District Of Monsey, N.Y 2Health News:Nationwide Tax Solutions Rebrands Itself as Tax Strategies 2
... scaleable device that works with ... plasma or buffy coat. The ... must be prepared independently using ... volume and concentration factor can ...
Avitene Microfibrillar Collagen (MCH) is used in surgical procedures as an adjunct to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical....
The Ultrafoam Collagen Sponge is indicated in all surgical procedures as an adjunct to hemostasis when control by ligature or conventional procedures are ineffective or impractical....
Exclusive oxidized regenerated cellulose technology. The only oxidized regenerated cellulose hemostat line, surgicel absorbable hemostat delivers a unique combination of effectiveness, absorbability,...
Medicine Products: